Company.

About

We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

 

Our initial focus is on developing our novel and proprietary 5- Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment Resistant Depression, or TRD.

 

Our portfolio currently includes GH001, our proprietary inhalable 5-MeO-DMT product candidate, and GH002, our proprietary injectable 5-MeO-DMT product candidate. Read about our pipeline here

 

We have completed a Phase 1 healthy volunteer clinical trial, in which administration of GH001 via inhalation was observed to be well tolerated at the investigated single dose levels and in an individualized dosing regimen with intra-subject dose escalation.

 

GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. Based on observed clinical activity, we believe that administration of a single dose of GH001 has the potential to induce ultra-rapid remissions as measured by the Montgomery-Åsberg Depression Rating Scale, or MADRS, in certain patients. The goal of the ongoing Phase 2 part of the trial is to assess whether an individualized dosing regimen with intra-subject dose escalation within a single day can further increase the MADRS remission rate as compared to a single GH001 dose.

Board of Directors

Florian Schönharting, M.Sc.

Co-Founder & Chairman of the Board

Mr. Schönharting founded or co-founded several biopharmaceutical companies, including Genmab A/S, Zealand Pharma A/S and Forward Pharma A/S. More than 25 years of investment executive experience in public and private equity funds involved in the biopharmaceutical industry. M.Sc. (Econ) from Copenhagen Business School.

Spike Loy, JD

Director

Mr. Loy has 10+ years’ experience as a life science investor and is currently Managing Director at BVF Partners L.P. He has a BA in Human Biology from Stanford University and a JD from Harvard Law School.

Michael Forer

Director

Michael Forer is Vice Chairman and Executive Vice President of ADC Therapeutics. Previously, Mr. Forer was a Managing Director of Auven Therapeutics and a co-founder of Rosetta Capital Limited, a London private equity firm focused on the life science sector.

Scientific Advisors

Malek Bajbouj, Prof. Dr. med.

Head, Center for Affective Neuroscience, Charité, Berlin

Prof. Bajbouj is head of the Center for Affective Neuroscience and the Global Mental Health Section and Managing Senior Physician at the department of psychiatry at Charité in Berlin. Published more than 220 articles mainly within affective disorders and innovative treatment options. Previous investigator in various ketamine and esketamine trials. Expert in early drug development, unipolar and post-partum depression.

Michael Bauer, Prof. Dr. rer. nat. Dr. med.

Chair, Department of Psychiatry and Psychotherapy, Medical Faculty, Technische Universität Dresden

Prof. Bauer is Director and Executive Chair, Physician-in-Chief at Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus in Dresden. Previous Visiting Professor of Psychiatry, UCLA, Neuropsychiatric Research Institute & Hospital, USA. Chairman, Task Force on the Biological Treatment Unipolar Depressive Disorders, World Federation of Societies of Biological Psychiatry. Expert in uni- and bipolar depression.

Johannes Ramaekers, Prof. Dr.

Professor, Faculty of Psychology and Neuroscience of Maastricht University

Prof. Ramaekers has extensively published on the impact of psychedelic substances on neuronal networks, cognitive function, mood, mindfulness and creativity and on their therapeutic implications. Further interest in behavioral toxicology of drugs where he combines methods from psychopharmacology, forensic toxicology and cognitive neuroscience to determine drug induced changes in human performance. His work bears relevance for drug development and legal settings when evaluating the impact of drug exposure on human function. Over 180 manuscripts.

Michael Thase, M.D.

Professor of Psychiatry and Chief, Division of Mood and Anxiety Disorders Treatment & Research Program, Perelman School of Medicine of the University of Pennsylvania

Prof. Michael Thase is Professor of Psychiatry and Chief, Division of Mood and Anxiety Disorders Treatment & Research Program at the Perelman School of Medicine of the University of Pennsylvania. His research focuses on the assessment and treatment of mood disorders, including both depression & bipolar affective disorder. Prof. Thase is a Distinguished Lifetime Fellow of the American Psychiatric Association, a Founding Fellow of the Academy of Cognitive Therapy, the Immediate Past President and a member of the Executive Committee of the Board of Directors of the American Society of Clinical Psychopharmacology, and a member of various advisory boards for the National Depression and Bipolar Support Alliance, the Anxiety and Depressive Disorders Association and the American Foundation for Suicide Prevention. Prof. Thase has been elected to the membership of the American College of Psychiatrists and he is a Fellow of the American College of Neuropsychopharmacology. He has authored or co-authored more than 900 scientific articles and book chapters, as well as 18 books, and has received numerous honors in his field.

Madhukar Trivedi, M.D.

Professor of Psychiatry and Chief of the Division of Mood Disorders, Department of Psychiatry at UT Southwestern Medical Center

Prof. Trivedi is Professor of Psychiatry in the Department of Psychiatry at UT Southwestern Medical Center. He is Chief of the Division of Mood Disorders and founding Director of the Center for Depression Research and Clinical Care, where he holds the Betty Jo Hay Distinguished Chair in Mental Health and the Julie K. Hersh Chair for Depression Research and Clinical Care. Prof. Trivedi is President-Elect of the American Society of Clinical Psychopharmacology. Prof. Trivedi is an internationally recognized translational researcher focusing on developing and validating biosignatures of depression. He also conducts research on pharmacological, psychosocial, and nonpharmacological treatments for depression. He has been a principal investigator on numerous translational research projects as well as clinical trials; has authored more than 500 peer-reviewed scholarly articles, numerous abstracts, and book chapters; and has delivered more than 200 invited lectures. Prof. Trivedi has received numerous local and international accolades.

Eduard Vieta, Prof. Dr.

Head, Psychiatry Unit, Hospital Clínic de Barcelona

Prof. Vieta is Professor of Psychiatry and Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic, where he also leads the Bipolar and Depressive Disorders Program. His unit is one of the worldwide leaders in clinical care, teaching, and research on affective disorders. Prof. Vieta is also the current Scientific Director of the Spanish Research Network on Mental Health (CIBERSAM). He has received several prestigious awards and research prizes. Twice named best psychiatrist in Spain. Authored more than 900 original articles, 450 book chapters and 43 books. Furthermore, he is an active clinical trialist and acted as neuroscience scientific advisor to the European Presidency.

Mark Zimmerman, M.D.

Professor of Psychiatry and Human Behavior, Brown University
Director of Outpatient Division and Partial Hospital Program, Rhode Island Hospital

Prof. Zimmerman is Professor in Psychiatry and Human Behavior at Brown University and Director of Outpatient Psychiatry and the Partial Hospital Program at Rhode Island Hospital, RI, United States. He is also the Director of the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project. Prof. Zimmerman has conducted research in psychiatry for more than two decades with a focus on the area of assessment and diagnosis of mental diseases. Prof. Zimmerman’s interest in assessment scale development is exemplified by the development of measures of the anxious distress and mixed features specifier of Major Depressive Disorder, and a measure of patient satisfaction. Prof. Zimmerman has more than 450 publications, is on the editorial board of eleven peer-reviewed journals, and is the associate editor of the Journal of Personality Disorders.